Optimizing Package Integrity Operations For Multiproduct CDMO Facilities

By Tyler Harris, Application Engineer, PTI

A growing pipeline of new and complex therapeutics has led to a monumental shift in business strategy across the pharmaceutical industry. The traditional approach of targeting one blockbuster drug to drive sales is a thing of the past, pushed to the wayside long ago by a combination of addressing unmet medical needs in smaller patient populations and an increased focus on efficiency and flexibility. Now, multiproduct manufacturing allows CDMOs to serve a wide range of clients and products, ultimately accelerating production and improving capacity utilization. Doing so successfully, though, while maintaining quality throughout the product’s life cycle until delivery can be challenging.

A critical component to achieving this is container closure integrity testing (CCIT), which offers assurance of a package’s ability to prevent loss and maintain product sterility.¹ However, the effectiveness of any CCIT method is based on physics and the interaction of the product and package characteristics. Find out how you as a CDMO can optimize operations in a multiproduct facility with many product and package combinations while also ensuring the package integrity testing technology you invest in can meet the needs of pharma manufacturers and their products.